[redacted]

(THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)

C

Sample Name	CEFIXIME DISPERSIBLE TABLETS-IP. 200mg.	**Mfg Lic No**	[redacted]
Submitted By	Quality Control Advisor. (MMDSL) Shillong.	**Report No**	
Address	DHS LaitumkhrahNHM,EastKhasi Hills Meghalaya.	**Receipt Date**	19-Mar-24
Mfg By	N.S.	**Report Date**	02-Apr-24
Supplied By	N.S.	**Ref No**	N.S.

Batch No	Mfg. Date	Exp Date	Batch Size	Sample Qty
MMDSL/QC-0144	05/2023	04/2025	N.S.	60 TABS.

RESULT OF ANALYSIS

Date / Period of Performance of test 19/03/2024 to 02/04/2024.

Reference to protocol :- I.P-2022.

Description :- Yellow coloured elongated biconvex uncoated dispersible tablets having scored on one side.

Identification (by HPLC) :- Complies.

Average weight :- 401.1mg.

Uniformity of weight :- Within limit.

Uniformity of dispersion :- Complies.

		Limit
Water(by KF)	:- 9.2%w/w	NMT 10%w/w
Disintegration Time	:- Within 1 min.	NMT:- 3 min.

Assay (by HPLC) :- Each uncoated dispersible tablet contains:-

Content of	Obtd./Av.wt.	Claim	LIMIT Lower	Upper	Method
Cefixime Trihydrate eq. to Anhydrous Cefixime	:- 198.62mg	200.0mg.	180.0mg.	220.0mg.	IP.

NOTE:- SAMPLE CONSUMED IN TESTING.

Report:In Opinion of the undersigned,The sample referred to above is of Standard Quality as defined in the Act and the rules made there under for the reason given: Complies as per IP.

[redacted]

NOTE : 1. The result listed refer only to the tested samples and applicable parameter. Endorsement of products is neither inferred nor implied.
2. Sample not drawn by us. Total liability of this laboratory limited to the invoice amount.
3. This report is not be reproduced wholly or in part and cannot be used as an evidence in the Court of Law and should not be used in any advertising media without special permission in writing.